Off-Label Ruling Opens Window For Shift In FDA Regulation, PhRMA Says
Executive Summary
PhRMA would like FDA to focus on the quality of off-label communication rather than the intent; one attorney says the Caronia decision may result in reduced government settlements and another warns of reading the ruling too favorably for industry.
You may also be interested in...
Off-label Ruling’s Potential Fallout Is “Terrifying,” FDA’s Temple Says
If firms could promote drugs for uses not backed by well-controlled studies, it would be “a nightmare,” Temple says; AEI’s Scott Gottlieb suggests the agency might try to regulate how medicines are prescribed.
Pfizer Settles Protonix Off-Label Allegations – Pricing Investigation Still Unresolved
Pfizer finalizes a $55 million settlement with the Department of Justice concerning Wyeth’s Protonix promotional practices; a separate probe of alleged bundling of Protonix sales to hospitals continues.
Off-Label Enforcement, Not Promotion, May See First Changes After Free Speech Ruling
In a watershed decision, a federal appeals court declares that manufacturers cannot be prosecuted under the FD&C Act’s misbranding provisions solely for speech promoting off-label use of a drug. Industry attorneys predict the decision, if it stands, will change the government’s approach to pursuing such cases.